Teprenone, but not H2-Receptor Blocker or Sucralfate, Suppresses Corpus Helicobacter pylori Colonization and Gastritis in Humans: Teprenone Inhibition of H. pylori-Induced Interleukin-8 in MKN28 Gastric Epithelial Cell Lines

Helicobacter

Volumn 9, Issue 2, 2004, Pages 130-137

  Miyake, Kazumasa ^a,b   Tsukui, Taku ^a   Shinji, Yoko ^a   Shinoki, Kei ^a   Hiratsuka, Tetsuro ^a   Nishigaki, Hitoshi ^a   Futagami, Seiji ^a   Wada, Ken ^a   Gudis, Katya ^a   Iwakiri, Katsuhiko ^a   Yamada, Nobutaka ^b   Sakamoto, Choitsu ^a  

^a Department of Pathology ^*  (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Helicobacter pylori; Histamine H2 receptor antagonists; Interleukin 8; Neutrophil infiltration; Sucralfate; Teprenone

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 8; NIZATIDINE; SUCRALFATE; TEPRENONE;

ADULT; ARTICLE; BACTERIAL COLONIZATION; CELL INFILTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EPITHELIUM; STOMACH MUCOSA;

ANTI-ULCER AGENTS; BIOPSY; CELL LINE; DITERPENES; EPITHELIAL CELLS; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHIL INFILTRATION; NIZATIDINE; PEPSINOGEN A; PEPSINOGEN C; SUCRALFATE; UREASE;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI;

EID: 11144353819     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1083-4389.2004.00209.x     Document Type: Article

References (44)

1. Yoshida N, Granger DN, Evans DJ Jr, et al. Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology 1993;105:1431-40.
2. Crabtree JE. Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage. Dig Dis Sci 1998;43:46S-55S.
3. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995;19:S37-43.
4. Crabtree JE, Lindley IJ. Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease. Eur J Gastroenterol Hepatol 1994; 6:S33-8.
5. Komoto K, Haruma K, Kamada T, et al. Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol 1998;93:1271-6.
6. Fan XG, Chua A, Fan XJ, Keeling PW. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995;48:133-6.
7. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425-9.
8. Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996;110:1744-52.
9. Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJ. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993;37:65-70.
10. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995;270: 11703-6.
11. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-9.
12. Arakawa T, Yamada H, Nakamura A, et al. Gastric cytoprotection by tetraprenylacetone in human subjects. Digestion 1988;39:111-7.
13. Shirakabe H, Takemoto T, Kobayashi K, et al. Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study. Clin Ther 1995;17:924-35.
14. Hassan S, Kinoshita Y, Okada A, Maekawa T, Fukui H, Chiba T. Geranylgeranylacetone, an anti-ulcer drug, stimulates hexosamine production in a rat gastric mucosal cell line through binding to a specific cytosolic protein. J Gastroenterol Hepatol 1998;13:809-15.
15. Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996; 111:345-57.
16. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
17. Fujimoto M, Yamanaka T, Bessho M, Igarashi T. Effects of geranylgeranylacetone on gastrointestinal secretion in rats. Eur J Pharmacol 1982;77: 113-8.
18. Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T, Okabe S. Effects of the antiulcer drug geranylgeranylacetone on aspirin-induced gastric ulcers in rats. Jpn J Pharmacol 1982;32:299-306.
19. Terano A, Shiga J, Hiraishi H, Ota S, Sugimoto T. Protective action of tetraprenylacetone against ethanol-induced damage in rat gastric mucosa. Digestion 1986;35:182-8.
20. Seno K, Joh T, Yokoyama Y, Itoh M. Role of mucus in gastric mucosal injury induced by local ischemia/reperfusion. J Lab Clin Med 1995;126: 287-93.
21. Ito M, Tanaka T, Suzuki Y. Increasing action of teprenone, a new antiulcer agent, on high-molecular-weight glycoprotein in gastric mucus during the healing process of acetic acid-induced ulcer in rats. Jpn J Pharmacol 1986;41:117-25.
22. Morimoto Y, Shimohara K, Oshima S, Sukamoto T. Effects of the new anti-ulcer agent KB-5492 on experimental gastric mucosal lesions and gastric mucosal defensive factors, as compared to those of teprenone and cimetidine. Jpn J Pharmacol 1991;57:495-505.
23. Hiraishi H, Terano A, Ota S, et al. Role for mucous glycoprotein in protecting cultured rat gastric mucosal cells against toxic oxygen metabolites. J Lab Clin Med 1993;121:570-8.
24. Nishida K, Ohta Y, Ishiguro I. Protective and preventive effects of teprenone on gastric mucosal lesions in rats. Eur J Pharmacol 1998;354:51-8.
25. Kobayashi T, Ohta Y, Yoshino J, Nakazawa S. Teprenone promotes the healing of acetic acid-induced chronic gastric ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues. Pharmacol Res 2001; 43:23-30.
26. Ishii E. Antibacterial activity of teprenone, a non water-soluble antiulcer agent, against Helicobacter pylori. Zentralbl Bakteriol 1993;280:239-43.
27. Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJ. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993;37:65-70.
28. Rieder G, Hatz RA, Moran AP, Walz A, Stolte M, Enders G. Role of adherence in interleukin-8 induction in Helicobacter pylori-associated gastritis. Infect Immun 1997;65:3622-30.
29. Yoshimura N, Suzuki Y, Saito Y. Suppression of Helicobacter pylori-induced interleukin-8 production in gastric cancer cell lines by an anti-ulcer drug, geranylgeranylacetone. J Gastroenterol Hepatol 2002;17:1153-60.
30. Nishisaki H, Sakamoto C, Konda Y, et al. Effects of antiulcer drugs on phosphatidylcholine synthesis in isolated guinea pig gastric glands. Dig Dis Sci 1992;37:1593-9.
31. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998;12:735-40.
32. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
33. Uemura N, Oomoto Y, Mukai T, et al. Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. Aliment Pharmacol Ther 1997;11:793-800.
34. Meining A, Bosseckert H, Caspary WF, Nauert C, Stolte M. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997;11:729-34.
35. Lam KT, Lai ST, Kan YS, Chan AY. Sucralfate compared with ranitidine in the short-term healing of duodenal ulcers. J Int Med Res 1985;13:338-41.
36. Tovey FI, Husband EM, Yiu YC, et al. Comparison of relapse rates and of mucosal abnormalities after healing of duodenal ulceration and after one' year's maintenance with cimetidine or sucralfate: a light and electron microscopy study. Gut 1989; 30:586-93.
37. Banerjee S, El-Omar E, Mowat A, et al. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Gastroenterology 1996;110: 717-24.
38. Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJ. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993;37:65-70.
39. Ohkusa T, Takashimizu I, Fujiki K, et al. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection. J Clin Gastroenterol 1997;25:317-22.
40. Perez-Paramo M, Albillos A, Calleja JL, et al. Changes in gastrin and serum pepsinogens in monitoring of Helicobacter pylori response to therapy. Dig Dis Sci 1997;42:1734-40.
41. Wagner S, Haruma K, Gladziwa U, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994;89: 1211-8.
42. Parente F, Maconi G, Sangaletti O, Minguzzi M, Vago L, Bianchi Porro G. Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of Helicobacter pylori in duodenal ulcer patients. A controlled study. Gut 1995;37:210-5.
43. Kreuning J, Lindeman J, Biemond I, Lamers CB. Serological parameters in assessment of degree of gastritis in healthy volunteers. Dig Dis Sci 1995; 40:609-14.
44. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.